BEAMSTART Logo

Wockhardt gains 4% as drug shows 97% efficacy for drug-resistant bacteria

Business Standard LogoBusiness Standard1d ago

Wockhardt gains 4% as drug shows 97% efficacy for drug-resistant bacteria - Business Standard

Quick Summary:

Wockhardt share price rose 3.96 per cent at Rs 1,441.95 per share on the BSE in intraday trade.

Treatment durations ranged from 7 to 21 days, and the study protocol was approved by the Drugs Controller General of India (DCGI).

At 12:42 PM, the stock price of the company advanced by 0.36 per cent at Rs 1392 a piece on the BSE.


More Pictures

Wockhardt gains 4% as drug shows 97% efficacy for drug-resistant bacteria - Business Standard (Picture 1)

or

Article Details

Category: BusinessFinance

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-01-13 @ 12:52:17 (1 days ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 389 words

Reading Time: 3 minutes read

Sentences: 17 lines

Sentence Length: 23 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 25100879

View Article Analysis

About Business Standard

Business Standard Logo

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 248 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 3 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "Wockhardt gains 4% as drug shows 97% efficacy for drug-resistant bacteria" has 389 words across 17 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Which news outlet covered this story?

The story "Wockhardt gains 4% as drug shows 97% efficacy for drug-resistant bacteria" was covered 1 days ago by Business Standard, a news publisher based in India.

How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news.

The outlet is headquartered in India and publishes an average of 248 news stories per day.

It's most recent story was published 3 hours ago.

What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #25100879
  • URL: https://beamstart.com/news/wockhardt-gains-4-as-drug-17367541732788

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2025 BEAMSTART. All Rights Reserved.